Skip to content

Study · Randomized controlled trial · n = 416 · 2019

8 results

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.

Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA11 Jan 2019Cited by 41 (Europe PMC)

PMID30635696 (opens in a new tab)PMCIDPMC6422956 (opens in a new tab)DOI10.1007/s00198-018-04819-1 (opens in a new tab)PepBankPUB-30635696
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In ACTIVE participants, the mean uncoupling index at month 1 was greater with abaloparatide than teriparatide, 1.743 versus 1.493.

    In plain wordsIn ACTIVE participants, the bone formation-resorption balance index at month 1 was higher with abaloparatide than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseUncoupling index at month 1
    Study

    n = 416

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean uncoupling index at 1 month
    1.743 index
    abaloparatide
    Mean uncoupling index at 1 month
    1.493 index
    teriparatide (comparator)

    Source sentences

    Summary
    The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  2. 02HumanRandomized controlled trialMechanism

    In ACTIVE participants, the uncoupling index was similar with abaloparatide and teriparatide at month 3 or later.

    In plain wordsIn ACTIVE participants, the bone formation-resorption balance index was similar with abaloparatide and teriparatide at month 3 or later.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeUncoupling index at month 3 or later
    Study

    n = 416

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  3. 03HumanObservational studyMechanism

    In ACTIVE participants, the PINP-BMD correlation was greater with abaloparatide than teriparatide, with r = 0.561 versus 0.198.

    In plain wordsIn ACTIVE participants, early PINP changes were more strongly linked to later bone density changes with abaloparatide than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePINP-BMD correlation
    Study

    n = 416

    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    PINP-BMD Pearson correlation
    0.561 r
    abaloparatide; log ratio of PINP at 3 months vs BMD percent change at 18 months
    PINP-BMD Pearson correlation
    0.198 r
    teriparatide (comparator); log ratio of PINP at 3 months vs BMD percent change at 18 months

    Source sentences

    Summary
    Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198).
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  4. 04HumanObservational studyMechanism

    In ACTIVE participants, the PINP-BMD correlation was lower with teriparatide than abaloparatide, with r = 0.198 versus 0.561.

    In plain wordsIn ACTIVE participants, early PINP changes were less strongly linked to later bone density changes with teriparatide than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePINP-BMD correlation
    Study

    n = 416

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    PINP-BMD Pearson correlation
    0.198 r
    teriparatide; log ratio of PINP at 3 months vs BMD percent change at 18 months
    PINP-BMD Pearson correlation
    0.561 r
    abaloparatide (comparator); log ratio of PINP at 3 months vs BMD percent change at 18 months

    Source sentences

    Summary
    Pearson correlations for the log ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with abaloparatide (r = 0.561) than teriparatide (r = 0.198).
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  5. 05HumanObservational studyMechanism

    In ACTIVE participants, the mean uncoupling index at month 1 was lower with teriparatide than abaloparatide, 1.493 versus 1.743.

    In plain wordsIn ACTIVE participants, the bone formation-resorption balance index at month 1 was lower with teriparatide than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseUncoupling index at month 1
    Study

    n = 416

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean uncoupling index at 1 month
    1.493 index
    teriparatide
    Mean uncoupling index at 1 month
    1.743 index
    abaloparatide (comparator)

    Source sentences

    Summary
    The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  6. 06HumanObservational studyMechanism

    In ACTIVE participants, the uncoupling index was similar with teriparatide and abaloparatide at month 3 or later.

    In plain wordsIn ACTIVE participants, the bone formation-resorption balance index was similar with teriparatide and abaloparatide at month 3 or later.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeUncoupling index at month 3 or later
    Study

    n = 416

    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mean UI at 1 month was greater for abaloparatide versus teriparatide (1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  7. 07HumanObservational studyMechanism

    In ACTIVE participants given teriparatide, early BTM changes were associated with subsequent BMD changes.

    In plain wordsIn ACTIVE participants given teriparatide, early bone marker changes were linked to later bone density changes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableEarly BTM and later BMD association
    Study

    n = 227

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Early BTM changes were associated with subsequent BMD changes for both treatments.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.
  8. 08HumanObservational studyMechanism

    In ACTIVE participants given abaloparatide, early BTM changes were associated with subsequent BMD changes.

    In plain wordsIn ACTIVE participants given abaloparatide, early bone marker changes were linked to later bone density changes.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableEarly BTM and later BMD association
    Study

    n = 189

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Early BTM changes were associated with subsequent BMD changes for both treatments.
    3 context sentences
    Summary · context
    Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6, 12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who completed the study.
    Summary · context
    BMD was measured by DXA at baseline, 6, 12, and 18 months.
    Summary · context
    Correlations were calculated between log ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.